IL21 and neoplasm: Although CAR T cells with activation-dependent IL-21 secretion (NFAT promoter-IL-21) displayed increased tumor infiltration in a chronic lymphocytic leukemia CDX model, no obvious improvement in anti-tumor efficacy has been reported (24).